Section I: Behavioral Neurology 1. Cholinesterase Inhibitors for Alzheimer's Disease 2. Memantine for Alzheimer's Disease Section II: Epilepsy 3. Lorazepam for Generalized Status Epilepticus 4. Lamotrigine for Partial Epilepsy: Arm A of the SANAD Trial 5. Valproate for Generalized and Unclassifiable Epilepsy: Arm B of the SANAD Trial Section III: Headache 6. Sumatriptan for Acute Migraine Section IV: Neuroinfectious Disease 7. Steroids for Bell's Palsy 8. Steroids for Acute Bacterial Meningitis Section V: Movement Disorders 9. Levadopa for Parkinson's Disease 10. Deep-Brain Stimulation for Parkinson's Disease Section VI: Multiple Sclerosis 11. Oral vs. IV Steroids for Acute Relapses of Multiple Sclerosis 12. Interferon Beta-1a for a First Demyelinating Event: The CHAMPS Trial 13. Glatiramer Acetate for Clinically Isolated Syndrome: The PreCISe Trial 14. Natalizumab for Relapsing Multiple Sclerosis: The SENTINEL Trial 15. Fingolimod for Relapsing Multiple Sclerosis: The TRANSFORMS Trial 16. Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part I: The DEFINE Trial17. Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part II: The CONFIRM Trial Section VII: Neurocritical Care 18. Therapeutic Hypothermia for Cardiac Arrest, Part I: The HACA Trial 19. Therapeutic Hypothermia for Cardiac Arrest, Part II: The Australian Trial 20. Decompressive Craniectomy for Diffuse Traumatic Brain Injury: The DECRA Trial 21. Nimodipine for Subarachnoid Hemorrhage Section VIII: Neuromuscular Disease 22. IVIG vs. Plasma Exchange for Guillain-Barre Syndrome 23. IVIG vs. Plasma Exchange for Myasthenia Gravis 24. Riluzole for Amyotrophic Lateral Sclerosis Section IX: Neuro-Oncology 25. Radiotherapy Plus Temozolomide for Glioblastoma 26. Methylated MGMT Gene Promoter and Response to Temozolomide for Glioblastoma Section X: Neuro-Ophthalmology 27. Steroids for Acute Optic Neuritis: The Optic Neuritis Treatment Trial Section XI: Neuro-Otology 28. The Epley Maneuver for Benign Paroxysmal Positional Vertigo Section XII: Sleep 29. Modafinil for Narcolepsy 30. Continuous Dopamine Agonist for Restless Legs Syndrome Section XIII: Spine Disorders 31. Early Surgery for Sciatica 32. Surgery for Lumbar Degenerative Spondylolisthesis: The SPORT Trial 33. Steroids vs. No Steroids for Acute Spinal Cord Injury: The NASCIS II Trial Section XIV: Vascular Neurology 34. IV Thrombolysis 3 Hours After an Acute Ischemic Stroke: The NINDS Trial 35. IV Thrombolysis 3 to 4.5 Hours After an Acute Ischemic Stroke: The ECASS III Trial 36. Endovascular Therapy for Acute Ischemic Stroke, Part I (Intra-arterial Thrombolysis): The PROACT II Trial 37. Endovascular Therapy for Acute Ischemic Stroke, Part II (After IV Thrombolysis): The IMS III Trial 38. Endovascular Therapy for Acute Ischemic Stroke, Part III (Using Neuroimaging to Select Patients): The MR RESCUE Trial 39. Endovascular Therapy for Acute Ischemic Stroke, Part IV (Clinical Trial Success): The MR CLEAN Trial 40. Carotid Endarterectomy for Symptomatic High-Grade Carotid Stenosis: The NASCET Trial, Part I 41. Carotid Endarterectomy for Symptomatic Moderate Carotid Stenosis: The NASCET Trial, Part II 42. Carotid Endarterectomy for Asymptomatic Carotid Stenosis: The ACAS Trial 43. Early Aspirin for Acute Ischemic Stroke: The CAST Trial 44. Aspirin vs. Heparin for Acute Ischemic Stroke: The IST Trial 45. Dipyridamole and Asprin for Secondary Stroke Prevention: The ESPS-2 Trial 46. High-Dose Atorvastatin After Stroke or Transient Ischemic Attack: The SPARCL Trial 47. Adjusted-Dose Warfarin for Stroke Prevention in High-Risk Atrial Fibrillation Patients: The SPAF III Trial 48. Dabigatran for Stroke Prevention in Atrial Fibrillation Patients: The RE-LY Trial 49. Apixaban for Stroke Prevention in Atrial Fibrillation Patients: The ARISTOTLE Trial 50. Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients: The ROCKET AF Trial
